Synchron Raises $200M Series D to Boost BCI Commercialization and Develop Next-Gen Technology
Synchron announced securing $200 million in a Series D funding round to accelerate the commercialization of its brain-computer interface (BCI) system. The New York-based company plans to use the capital to fast-track its Stentrode BCI launch and advance development of a next-generation interface.
Funding Details and Strategic Plans
This financing brings Synchron's total funding to $345 million. The company aims to accelerate pivotal clinical trials and expand its team by hiring engineers, neuroscientists, and operators to support next-generation BCI innovation.
Synchron is also growing its Cognitive AI division in New York to develop models that decode thought in real time by learning from brain data. Additionally, a new engineering hub in San Diego has been established to focus on building more advanced brain interfaces.
Investors Involved
- Double Point Ventures led the round
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
About the Stentrode BCI
Synchron says its BCI is the only one that captures brain signals through blood vessels. The Stentrode implant, placed on the motor cortex surface via the jugular vein, detects motor intention from within brain blood vessels.
The Stentrode is implanted using an endovascular approach, offering a unique method to tap into brain signals compared to traditional systems.
Author's summary: Synchron’s $200M funding aims to fast-track its innovative Stentrode BCI’s launch and develop advanced brain-computer interfaces through expanded teams and AI-driven brain data decoding.